UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Journal of clinical oncology, 2017-04, Vol.35 (10), p.1112-1118

2017

Volltextzugriff (PDF)

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-10, Vol.23 (19), p.5703-5710

2017

Volltextzugriff (PDF)

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

The New England journal of medicine, 2016-02, Vol.374 (8), p.738-748

2016

Volltextzugriff (PDF)

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.425-429

2019

Volltextzugriff (PDF)

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Gynecologic oncology, 2015-02, Vol.136 (2), p.246-253

2015

Volltextzugriff (PDF)

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Gynecologic oncology, 2021-11, Vol.163 (2), p.246-253

2021

Volltextzugriff (PDF)

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

Clinical cancer research, 2019-03, Vol.25 (6), p.1727-1736

2019

Volltextzugriff (PDF)

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2569-2575

2015

Volltextzugriff (PDF)

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Gynecologic oncology, 2018-03, Vol.148 (3), p.507-514

2018

Volltextzugriff (PDF)

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic oncology, 2017-11, Vol.147 (2), p.402-407

2017

Volltextzugriff (PDF)

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

The New England journal of medicine, 2023-12, Vol.389 (23), p.2162-2174

2023

Volltextzugriff (PDF)

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Gynecologic oncology, 2024-06, Vol.185, p.186-193

2024

Volltextzugriff (PDF)

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Journal of clinical oncology, 2016-07, Vol.34 (19), p.2279-2286

2016

Volltextzugriff (PDF)

Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition

Journal of clinical oncology, 2007-07, Vol.25 (20), p.2894-2901

2007

Volltextzugriff (PDF)

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Clinical cancer research, 2023-04, Vol.29 (8), p.1515-1527

2023

Volltextzugriff (PDF)

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Gynecologic oncology, 2019-12, Vol.155 (3), p.420-428

2019

Volltextzugriff (PDF)

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Journal of clinical oncology, 2024-07, Vol.42 (21), p.2537-2545

2024

Volltextzugriff (PDF)

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic oncology, 2018-09, Vol.150 (3), p.466-470

2018

Volltextzugriff (PDF)

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Seminars in oncology, 2009-04, Vol.36 (2), p.112-125

2009

Volltextzugriff (PDF)

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis

Journal of the National Comprehensive Cancer Network, 2017-10, Vol.15 (10), p.1224-1233

2017

Volltextzugriff (PDF)

Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system

Journal of oncology pharmacy practice, 2022-07, Vol.28 (5), p.1102-1110

2022

Volltextzugriff (PDF)

Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

Clinical cancer research, 2013-09, Vol.19 (18), p.5053-5067

2013

Volltextzugriff (PDF)

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

Gynecologic oncology, 2012-12, Vol.127 (3), p.451-455

2012

Volltextzugriff (PDF)

CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study

Clinical cancer research, 2017-07, Vol.23 (14), p.3684-3691

2017

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis

Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system

Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study

Aktive Filter

Suchergebnisse filtern